News & Updates

Show Multimedia Only

IBD therapies do not increase risk of contracting COVID-19 after immunization

18 Dec 2021 by

Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.

18 Dec 2021

Early vedolizumab treatment uncommon in IBD

17 Dec 2021 by

In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.

17 Dec 2021

Wrist strap monitors physiological changes in IBD

17 Dec 2021 by

A novel health tracker that is strapped around the wrist can detect changes in the physiology of individuals with inflammatory bowel disease (IBD) in real time, as shown in a study presented at the Advances in Inflammatory Bowel Diseases conference.

17 Dec 2021

TC-325 on par with standard treatment for control of bleeding from upper nonvariceal lesions

17 Dec 2021

The hemostatic powder TC-325 has demonstrated its noninferiority to standard treatment in the endoscopic control of bleeding from nonvariceal upper gastrointestinal causes, reports a study.

17 Dec 2021

Certain IBD meds tied to excess risk of COVID-19 hospitalization

16 Dec 2021 by

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

16 Dec 2021

NAFLD prevalent in IBD patients

16 Dec 2021 by

The incidence of nonalcoholic fatty liver disease (NAFLD) is high among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2021.

16 Dec 2021

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

15 Dec 2021 by

Treatment with the anti-interleukin (IL)-12/-23 monoclonal antibody ustekinumab yields a high rate of clinical remission in patients with moderate-to-severe Crohn’s disease (CD) in the real-world setting, according to a study presented at AIBD 2021.

15 Dec 2021

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

15 Dec 2021

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

15 Dec 2021

Too much processed meat ups mortality risk in IBD patients

15 Dec 2021 by

Frequent consumption of processed meat was found to be associated with an increased risk of mortality in individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2021. Conversely, this association was not seen with fish and unprocessed meat consumption.

15 Dec 2021

Probiotic use in IBD may cloud the mind

14 Dec 2021 by

Patients with inflammatory bowel disease (IBD) who consume probiotics can develop brain fog, especially men and those who are Caucasian, as suggested in a study.

14 Dec 2021

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

IBD therapies do not increase risk of contracting COVID-19 after immunization

Early vedolizumab treatment uncommon in IBD

Wrist strap monitors physiological changes in IBD

TC-325 on par with standard treatment for control of bleeding from upper nonvariceal lesions

Certain IBD meds tied to excess risk of COVID-19 hospitalization

NAFLD prevalent in IBD patients

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

Too much processed meat ups mortality risk in IBD patients

Probiotic use in IBD may cloud the mind